<DOC>
	<DOCNO>NCT00690118</DOCNO>
	<brief_summary>Primary objective : Efficacy pioglitazone ( 45 mg/day ) add-on therapy standard therapy riluzole patient ALS compare placebo term survival ( mortality define exclusively death ) . This prospective , multicentre , randomise , stratify , parallel-group , double-blind trial compare placebo 45 mg pioglitazone add-on therapy 100 mg riluzole ALS 220 enrol patient . For entry , El Escorial Criteria diagnosis use . The duration treatment 18 month . The primary endpoint subject confirmatory analysis . Secondary variable incidence tracheotomy non-invasive ventilation , ALS Functional Rating Scale , Quality life safety variable .</brief_summary>
	<brief_title>Study Pioglitazone Patients With Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>possible , probable ( clinically laboratory ) definite ALS accord revise version El Escorial World Federation Neurology criterion disease duration 6 month le 3 year bestsitting FVC 50 % 95 % predict normal continuously treat 100 mg riluzole daily , least one month onset progression weakness within 36 month prior study woman childbearing age nonlactating surgically sterile use highly effective method birth control negative pregnancy test capable thoroughly understand information give give full inform consent accord GCP previous participation another clinical study within precede three month tracheotomy assist ventilation type precede three month gastrostomy medical condition know association motor neuron dysfunction might confound obscure diagnosis ALS presence concomitant lifethreatening disease impairment likely interfere functional assessment confirm hepatic insufficiency abnormal liver function ( ASAT and/or ALAT 1.5 upper limit normal ) renal insufficiency ( serum creatinine 2.26 mg/dl ) evidence major psychiatric disorder clinically evident dementia preclude evaluation symptom know hypersensitivity component study drug likely cooperative comply trial requirement ( assessed investigator ) , unable reach case emergency antidiabetic heart failure heart failure patient history ( NYHA I IV ) history macular oedema treatment thiazolidinediones within 3 month prior screen know suspected history alcohol and/or drug abuse treatment gemfibrozil within 3 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>amyotrophic lateral sclerosis</keyword>
	<keyword>survival time</keyword>
	<keyword>ALS function Rating Scale</keyword>
	<keyword>quality life</keyword>
	<keyword>non-invasive ventilation</keyword>
	<keyword>clinical tolerability</keyword>
	<keyword>survival</keyword>
</DOC>